{"d":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Subject(ID=38857L,Language='IT')","uri":"https://ws.parlament.ch/OData.svc/Subject(ID=38857L,Language='IT')","type":"itsystems.Pd.DataServices.DataModel.Subject"},"Meetings":{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Meeting(ID=3880L,Language='IT')","uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=3880L,Language='IT')","type":"itsystems.Pd.DataServices.DataModel.Meeting"},"Sessions":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=3880L,Language='IT')/Sessions"}},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Meeting(ID=3880L,Language='IT')/Subjects"}},"ID":"3880","Language":"IT","MeetingNumber":9,"IdSession":5006,"SessionNumber":6,"SessionName":"Sessione invernale 2016","Council":1,"CouncilName":"Consiglio nazionale","CouncilAbbreviation":"CN","Date":"\/Date(1481500800000)\/","Begin":"1430","Modified":"\/Date(1485183182127)\/","LegislativePeriodNumber":50,"PublicationStatus":"final","MeetingOrderText":"Nona seduta","SortOrder":9,"Location":"N"},"SubjectsBusiness":{"results":[{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20165549,IdSubject=38857L,Language='IT')","uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20165549,IdSubject=38857L,Language='IT')","type":"itsystems.Pd.DataServices.DataModel.SubjectBusiness"},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20165549,IdSubject=38857L,Language='IT')/Subjects"}},"Businesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/SubjectBusiness(BusinessNumber=20165549,IdSubject=38857L,Language='IT')/Businesses"}},"IdSubject":"38857","BusinessNumber":20165549,"Language":"IT","BusinessShortNumber":"16.5549","Title":"Heure des questions.\nQuestion Fehlmann Rielle Laurence.\nAvastin. Pourquoi ne pas autoriser\nun m\u00e9dicament efficace\net \u00e0 un prix modique?","SortOrder":1,"PublishedNotes":null,"Modified":"\/Date(1481820274790)\/","TitleDE":"Fragestunde.\nFrage Fehlmann Rielle Laurence.\nAvastin. Warum wird das effiziente\nund preiswerte Medikament\nnicht zugelassen?","TitleFR":"Heure des questions.\nQuestion Fehlmann Rielle Laurence.\nAvastin. Pourquoi ne pas autoriser\nun m\u00e9dicament efficace\net \u00e0 un prix modique?","TitleIT":null}]},"Transcripts":{"results":[{"__metadata":{"id":"https://ws.parlament.ch/OData.svc/Transcript(ID=208830L,Language='IT')","uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=208830L,Language='IT')","type":"itsystems.Pd.DataServices.DataModel.Transcript"},"Subjects":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=208830L,Language='IT')/Subjects"}},"MembersCouncil":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=208830L,Language='IT')/MembersCouncil"}},"Businesses":{"__deferred":{"uri":"https://ws.parlament.ch/OData.svc/Transcript(ID=208830L,Language='IT')/Businesses"}},"ID":"208830","Language":"IT","IdSubject":"38857","VoteId":null,"PersonNumber":1161,"Type":1,"Text":"<pd_text><p>Selon le droit actuel, une entreprise pharmaceutique peut d\u00e9cider elle-m\u00eame quels m\u00e9dicaments elle entend faire homologuer et mettre sur le march\u00e9 et pour quelle indication. Cette r\u00e8gle tient au fait que l'entreprise pharmaceutique assume l'enti\u00e8re responsabilit\u00e9 du m\u00e9dicament et que, conform\u00e9ment au droit de la responsabilit\u00e9 civile en mati\u00e8re de produits, elle doit en garantir le caract\u00e8re irr\u00e9prochable.</p>\n<p>Cela signifie donc que la Conf\u00e9d\u00e9ration ne dispose pas des bases l\u00e9gales qui lui permettraient d'obliger les entreprises pharmaceutiques \u00e0 faire autoriser un nouveau m\u00e9dicament ou \u00e0 \u00e9tendre l'indication d'un m\u00e9dicament existant. De ce fait, elle ne peut pas non plus exiger que des \u00e9tudes cliniques comparatives soient r\u00e9alis\u00e9es afin d'utiliser un m\u00e9dicament pour une indication qui n'est pas autoris\u00e9e en Suisse.</p>\n<p>Un principe similaire vaut d'ailleurs pour le remboursement par l'assurance obligatoire des soins, puisque seuls les m\u00e9dicaments utilis\u00e9s pour une indication autoris\u00e9e par Swissmedic peuvent \u00eatre rembours\u00e9s.</p>\n</pd_text>","MeetingCouncilAbbreviation":"N","MeetingDate":"20161212","MeetingVerbalixOid":2823,"IdSession":"5006","SpeakerFirstName":"Alain","SpeakerLastName":"Berset","SpeakerFullName":"Berset Alain","SpeakerFunction":"BR-M","CouncilId":99,"CouncilName":"Consiglio federale","CantonId":10,"CantonName":"Friburgo","CantonAbbreviation":"FR","ParlGroupName":null,"ParlGroupAbbreviation":null,"SortOrder":1,"Start":"\/Date(1481556017808)\/","End":"\/Date(1481556119488)\/","Function":"BR-M","DisplaySpeaker":true,"LanguageOfText":"FR","Modified":"\/Date(1774877348154)\/","StartTimeWithTimezone":"\/Date(1481556017807+0060)\/","EndTimeWithTimezone":"\/Date(1481556119487+0060)\/","VoteBusinessNumber":null,"VoteBusinessShortNumber":null,"VoteBusinessTitle":null}]},"ID":"38857","Language":"IT","IdMeeting":"3880","VerbalixOid":511554,"SortOrder":27,"Modified":"\/Date(1774877348150)\/"}}